China presents safe vaccine that generates immune response against Covid-19


Participants, aged between 18 and 60 years, were randomly given one of three types of vaccine dosages: with low, medium and high concentration of the viral agent.

According to the research, the adverse reactions observed were pain, fatigue, fever, headache and muscle pain, common in immunizations for other diseases. Most participants reported mild or moderate effects, and no serious effects were seen within these 28 days.

Phase 1 is the first stage of the study in humans and its main objective is to test the safety of the vaccine. Usually, few volunteers are tested. Phase 2, on the other hand, analyzes security and effectiveness in more detail, and a larger group participates, sometimes hundreds of people.

Other vaccines

This week, the American pharmaceutical group Moderna announced encouraging results from an experimental vaccine against the new coronavirus. The company reported that, in an early phase of its study, led by the US National Institute of Allergy and Infectious Diseases (NIAID), eight of the 45 participants developed neutralizing antibodies to Covid-19 after 43 days and two doses.

However, the publication of an article on the scientific news portal “Stat News”, in which vaccine experts urged caution with the test results, created uncertainty. They claim that the US government has not commented on this and that the preliminary results refer only to eight of the 45 study participants.

Oxford University and AstraZeneca said today who plan to recruit 10,260 UK adults and children for testing an experimental vaccine against the new coronavirus. The idea is to analyze how the human immune system reacts to the vaccine and its safety.

An initial test, which started on April 23, has already given the injection to more than 1,000 volunteers, aged between 18 and 55 years. Oxford said that phases two and three will add people aged 56 and older, as well as children aged 5 to 12.

Source link


Please enter your comment!
Please enter your name here